Ye E Huang, 6133873 Summerfields Dr, Gurnee, IL 60031

2005015, Jul 21, 2005

Sep 24, 2004

10/949141

Evangeline Cruz - Hayward CA, US
Atul Ayer - Palo Alto CA, US
Brenda Pollock - Cupertino CA, US
Carmelita Garcia - Newark CA, US
Sherry Li - Cupertino CA, US
Alfredo Wong - Sunnyvale CA, US
Lawrence Hamel - Mountain View CA, US
Cheri Klein - Northbrook IL, US
Yihong Qiu - Vernon Hills IL, US
Ye Huang - Gurnee IL, US

A61K031/485
A61K031/16
A61K009/22

424468000, 514282000, 514629000

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

2006025, Nov 9, 2006

Jun 30, 2006

11/480124

Evangeline Cruz - Hayward CA, US
Atul Ayer - Palo Alto CA, US
Brenda Pollock - Cupertino CA, US
Carmelita Garcia - Newark CA, US
Sherry Li - Cupertino CA, US
Alfredo Wong - Sunnyvale CA, US
Lawrence Hamel - Mountain View CA, US
Cheri Klein - Northbrook IL, US
Yihong Qiu - Vernon Hills IL, US
Ye Huang - Gurnee IL, US

A61K 31/485
A61K 9/22
A61K 31/16

424468000, 514282000, 514625000

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

2010022, Sep 2, 2010

Mar 2, 2010

12/716086

Evangeline Cruz - Hayward CA, US
Atul D. Ayer - Palo Alto CA, US
Brenda J. Pollock - Cupertino CA, US
Carmelita Garcia - Newark CA, US
Sherry Li - Cupertino CA, US
Alfredo M. Wong - Sunnyvale CA, US
Lawrence G. Hamel - Mountain View CA, US
Cheri Enders Klein - Northbrook IL, US
Yihong Qiu - Vernon Hills IL, US
Ye Huang - Gurnee IL, US

A61K 31/485
A61K 9/00
A61P 25/00

424400, 514282

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

2012016, Jun 28, 2012

Nov 18, 2011

13/300380

Evangeline Cruz - Hayward CA, US
Atul D. Ayer - Palo Alto CA, US
Brenda J. Pollock - Cupertino CA, US
Carmelita Garcia - Newark CA, US
Sherry Li - Cupertino CA, US
Alfredo M. Wong - Sunnyvale CA, US
Lawrence G. Hamel - Mountain View CA, US
Cheri Enders Klein - Northbrook IL, US
Yihong Qiu - Vernon Hills IL, US
Ye Huang - Gurnee IL, US

A61K 31/485
A61P 25/04
A61P 29/00

514282

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

2012025, Oct 4, 2012

Mar 30, 2012

13/436727

Evangeline Cruz - Hayward CA, US
Atul D. Ayer - Palo Alto CA, US
Brenda J. Pollock - Cupertino CA, US
Carmelita Garcia - Newark CA, US
Sherry Li - Cupertino CA, US
Alfredo M. Wong - Sunnyvale CA, US
Lawrence G. Hamel - Mountain View CA, US
Cheri Enders Klein - Northbrook IL, US
Yihong Qiu - Vernon Hills IL, US
Ye Huang - Gurnee IL, US

A61K 9/00
A61P 25/04
A61P 29/00
A61K 31/485

424400, 514282

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic.

2013020, Aug 15, 2013

Feb 28, 2013

13/781420

ALZA CORPORATION - , US
Atul D. Ayer - Pslo Alto CA, US
Brenda J. Pollock - Cupertino CA, US
Carmelita Garcia - Newark CA, US
Sherry Li - Cupertino CA, US
Alfredo M. Wong - Sunnyvale CA, US
Lawrence G. Hamel - Mountain View CA, US
Cheri Enders Klein - Northbrook IL, US
Yihong Qiu - Vernon Hills IL, US
Ye Huang - Gurnee IL, US

ALZA CORPORATION - New Brunswick NJ

A61K 31/485
A61K 9/20
A61K 31/167

424400, 514282

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

2014004, Feb 13, 2014

Oct 21, 2013

14/059367

Atul D. Ayer - Palo CA, US
Brenda J. Pollock - Cupertino CA, US
Carmelita Garcia - Newark CA, US
Sherry Li - Cupertino CA, US
Alfredo M. Wong - Sunnyvale CA, US
Lawrence G. Hamel - Mountain View CA, US
Cheri Enders Klein - Northbrook IL, US
Yihong Qiu - Vernon Hills IL, US
Ye Huang - Gurnee IL, US

ALZA CORPORATION - New Brunswick NJ

A61K 9/20
A61K 31/167
A61K 31/485

424464, 514282

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

2023012, Apr 27, 2023

Aug 3, 2022

17/817191

- North Chicago IL, US
Ye HUANG - Gurnee IL, US
John M. LIPARI - Mount Pleasant WI, US
Alexander RUGGLES - Lake Forest IL, US
Thin Yu TUN - Gurnee IL, US

AbbVie Inc. - North Chicago IL

A61K 31/198
A61K 47/32
A61K 47/10
A61K 47/38
A61K 9/10
A61K 9/00
A61K 31/195

The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.